Logo

BGLC

BioNexus Gene Lab Corp.

BGLC

BioNexus Gene Lab Corp. • NASDAQ
$4.54 ▲ 0.00% (+0.00)
Market Cap $8.16 M
52w High $15.60
52w Low $2.01
Dividend Yield 0%
P/E -3.55
Volume 3.22K
Outstanding Shares 1.80M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $2.544M ▲ $1.08M ▲ $-708.991K ▼ -27.871% ▼ $-0.39 ▼ $-665.636K ▼
Q2-2025 $2.26M ▲ $979.315K ▲ $-616.172K ▲ -27.261% ▲ $-0.34 ▲ $-569.56K ▼
Q1-2025 $2.137M ▼ $961.911K ▲ $-623.327K ▼ -29.167% ▼ $-0.35 ▼ $-546.916K ▼
Q4-2024 $2.524M ▼ $725.454K ▼ $-348.319K ▲ -13.801% ▲ $-0.19 ▲ $-373.199K ▲
Q3-2024 $2.63M $1.664M $-1.345M -51.147% $-0.75 $-1.289M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $2.895M ▼ $7.621M ▼ $804.966K ▼ $6.816M ▼
Q2-2025 $3.059M ▼ $9.421M ▼ $1.899M ▲ $7.522M ▼
Q1-2025 $3.595M ▼ $9.48M ▼ $1.708M ▼ $7.772M ▼
Q4-2024 $4.377M ▲ $10.434M ▼ $2.111M ▲ $8.323M ▼
Q3-2024 $4.137M $10.995M $1.607M $9.388M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-708.991K ▼ $-1.233M ▼ $990.454K ▲ $34.187K ▲ $-164.225K ▲ $-1.239M ▼
Q2-2025 $-616.172K ▲ $-737.907K ▲ $-28.532K ▼ $-1.03K ▼ $-552.249K ▲ $-759.366K ▲
Q1-2025 $-623.327K ▼ $-824.072K ▼ $-15.646K ▼ $-860 ▼ $-797.528K ▼ $-833.124K ▼
Q4-2024 $-348.319K ▲ $-54.32K ▲ $485.681K ▲ $139.613K ▲ $240.208K ▲ $-58.34K ▲
Q3-2024 $-1.345M $-1.423M $-221.942K $-196.982K $-1.277M $-1.622M

Five-Year Company Overview

Income Statement

Income Statement The income statement points to a company that is still essentially at a pre-commercial or very early commercial stage. Reported revenue has been tiny and flat for several years, with no meaningful gross profit or operating profit showing up. Net results swing around on paper, but that seems more tied to accounting items and share changes than to a real operating business. In plain terms, the core operations are not yet generating visible economic performance, and the story here is about future potential rather than current earnings power.

Balance Sheet

Balance Sheet The balance sheet is very small and simple: modest assets, no debt, and a thin layer of equity. Cash has moved around but remains limited, so the company appears highly dependent on external funding rather than internally generated cash. Multiple reverse stock splits also hint at a history of share price pressure and the need to stay compliant with listing rules. Overall, the financial foundation looks clean but fragile, with little buffer if plans take longer or cost more than expected.

Cash Flow

Cash Flow Cash flow data show no meaningful operating cash inflows and no visible investment spending at scale. That fits a business that is still in a build-out phase and not yet at commercial traction. The absence of strong cash burn is positive on the surface, but it likely reflects small scale rather than financial strength. Looking forward, any ramp-up in commercialization, regulatory work, sales teams, or clinical validation will almost certainly require more cash than the current profile suggests, making access to fresh capital an ongoing key risk.

Competitive Edge

Competitive Edge Competitively, BioNexus is trying to carve out a niche rather than go head‑to‑head with the biggest global diagnostics names. Its strengths lie in exclusive rights to a low-cost liquid biopsy platform in Southeast Asia, a clear price advantage for cancer monitoring, and partnerships that bring in advanced technology without bearing all the R&D alone. However, it is a tiny player in a field dominated by very large, well-funded companies. Success will depend on execution in specific regional markets, obtaining and maintaining regulatory approvals, building trust with clinicians, and defending its position as bigger players also move down the cost curve or into its target geographies.

Innovation and R&D

Innovation and R&D Innovation is the main asset here. The company is built around differentiated diagnostic ideas: a tumor‑naïve, liquid biopsy test for minimal residual disease at much lower cost, an RNA-based screening platform for early disease risk, and an early move into regenerative medicine through partnerships. It is also experimenting with an unconventional digital asset treasury and AI-driven diagnostics. These are ambitious and, if validated and adopted, could be powerful. At the same time, most of this is still at the proof, regulatory, or commercialization stage, not yet established as standard of care. Limited financial resources heighten the risk that promising science may be slowed or constrained by funding and operational capacity.

Summary

BioNexus Gene Lab is an early-stage, innovation-heavy diagnostics company with very small current financials and a high dependence on future execution. The financial statements show almost no scale, no demonstrated profitability, and a thin capital base, all of which make the business sensitive to funding conditions and delays. On the other side of the ledger, the company has outlined a clear strategic focus: cost-disruptive liquid biopsy, RNA-based screening, and selective regional rights in growing Southeast Asian healthcare markets, plus a toehold in regenerative medicine. The overall picture is a high-uncertainty, high-dependence-on-execution story, where outcomes will hinge more on clinical validation, regulatory approvals, and commercial rollout than on current financial trends.

NEWS

November 12, 2025 · 8:00 AM UTC

BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization

Read more

November 10, 2025 · 8:00 AM UTC

BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities

Read more

October 20, 2025 · 8:00 AM UTC

BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc.

Read more